

INNOVATIVE RESEARCH, CUTTING-EDGE THERAPIES

Through Specialty Care Centers of UPMC Hillman Cancer Center

Clinical trials are an opportunity for your patients to benefit from advances being made at UPMC Hillman Cancer Center, which is recognized both nationally and internationally for its translational research programs.

For a complete list of current research initiatives, or for more information about patient care, call **412-623-4861** or visit **Hillman.UPMC.com**.



UPMC | **HILLMAN
CANCER CENTER**

Ongoing Clinical Trials

Adult Brain Cancer

UPCI 16-185: Individualized screening trial of innovative glioblastoma therapy (INSIGHT).

UPCI 16-024: A Phase I trial of Anti-LAG-3 or Anti-CD137 alone and in combination with Anti-PD-1 in patients with recurrent GBM.

Bladder Cancer

UPCI 16-171: A randomized Phase II trial of cisplatin/gemcitabine with or without VX-970 in metastatic urothelial carcinoma.

UPCI 16-188: An open label, non-randomized, Phase I dose escalation study to characterize safety, tolerability, pharmacokinetics and maximum tolerated dose of BAY 1163877 in subjects with refractory, locally advanced, or metastatic solid tumors.

Breast Cancer

UPCI 17-016 (S1418): A randomized, Phase III trial to evaluate the efficacy and safety of MK-3475 (pembrolizumab) as adjuvant therapy for triple negative receptor-negative BC with >1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neo-adjuvant chemotherapy.

UPCI 7-113 (SHERBOC): A double-blind, placebo-controlled, Phase II trial of seribantumab plus fulvestrant in postmenopausal women with hormone receptor-positive, heregulin positive (HRG+), HER2 negative metastatic breast cancer whose disease progressed after prior systemic therapy.

Colorectal Cancer

UPCI 17-202: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) Study: A randomized Phase III study of mFOLFOX6/Bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first line treatment of patients with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer.

UPCI 16-123: A Phase IB/II study of epacadostat (INCBO24360) in combination with pembrolizumab (MK-3475) and azacitidine in subjects with chemo-refractory metastatic colon cancer.

Esophageal/Gastric Cancer

UPCI 17-077: MK3475 protocol 590: A randomized, double-blind, placebo-controlled phase III clinical trial of pembrolizumab (MK-3475) in combination with cisplatin and 5-fluorouracil vs. placebo in combination with cisplatin and 5 F-fluorouracil as first line treatment in subjects with advanced/metastatic esophageal carcinoma.

Head and Neck Cancer

UPCI 15-185: A Phase I/IIa dose escalation and cohort expansion study of the safety, tolerability, and efficacy of Anti-LAG-3 monoclonal antibody (BMS-986016) administered alone and in combination with anti-PD-1 monoclonal antibody (nivolumab, BMS-936558) in advanced solid tumors.

UPCI 15-132: A randomized, Phase II study evaluating concurrent or sequential fixed-dose of pembrolizumab in combination with cisplatin and intensity modulated radiotherapy (IMRT) in intermediate or high-risk, previously untreated, locally advanced head and neck cancer.

Kidney Cancer

UPCI 17-019: EA8143: A Phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).

UPCI 16-074: A multicenter, open-label, randomized Phase II study of AGS-16C3F vs. axitinib in metastatic renal cell carcinoma.

UPCI 17-018: A randomized, double-blind, Phase II trial to assess safety and efficacy of lenvatinib at two different starting doses (18 mg. vs. 14 mg QD) in combination with everolimus (5 mg QD) in renal cell carcinoma following one prior VEGF-targeted treatment.

Leukemia

UPCI 15-101: A Phase II study of pembrolizumab as post-remission > 60 AML not transplant candidates.

UPCI 15-060: A Phase II study evaluating selective depletion of CD45RA+ T cells from allogeneic peripheral blood stem cell grafts from HLA-matched related and unrelated donors for prevention of GVHD.

UPCI 17-050: A randomized, double blind, placebo-controlled study of ABT 199 co-administered with low dose cytarabine vs. low dose cytarabine in treatment of naïve patient with AML who are ineligible for intensive chemotherapy.

Lung Cancer

UPCI 16-153: A Phase II clinical trial evaluating the efficacy of atezolizumab in advanced non-small cell lung cancer (NSCLC) patients previously treated with PD-1-directed therapy.

UPCI 16-054: A Phase II clinical trial evaluating the safety and efficacy of durvalumab (MEDI4736) as 1st line therapy in advanced non-small cell lung cancer (NSCLC) patients with Eastern Cooperative Oncology Group (ECOG) performance status of 2.

Lymphoma

UPCI 16-070: A Phase III randomized open label trial to compare pembrolizumab with brentuximab vedotin in subjects with relapsed or refractory classical Hodgkin lymphoma.

UPCI 16-098: A Phase II study of AT13387 in refractory and/or relapsed ALK + ALCL, MCL and BCL 6 + DLBCL.

Melanoma

UPCI 17-085: A Phase I dose escalation and cohort expansion study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients with advanced solid tumors.

UPCI 16-196: Profiling and reversing metabolic insufficiency in the tumor microenvironment in advanced melanoma: A trial of pembrolizumab and metformin vs. pembrolizumab alone in advanced melanoma.

UPCI 17-034: Phase II feasibility study of fecal microbiota transplant (FMT) in advanced melanoma patients not responding to PD-1 blockade.

Neuroendocrine Cancer

UPCI 15-179: Randomized Phase II study of cisplatin and etoposide vs. temozolomide and capecitabine in patients with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas.

Pancreatic Cancer

UPCI 17-134: Randomized Phase II trial of pre-operative Gemcitabine, nab-paclitaxel, and hydroxychloroquine (PGH) with or without avelumab (PGH-A).

UPCI 15-176: A Phase III, randomized, double-blind, placebo-controlled, multicenter study of PEGylated recombinant human hyaluronidase (PEGPH20) in combination with nab-paclitaxel plus gemcitabine compared with placebo plus nab-paclitaxel and gemcitabine in subjects with hyaluronan-high stage IV previously untreated pancreatic ductal adenocarcinoma.

UPCI 16-203: A randomized Phase III study of AM0010 in combination with FOLFOX compared with FOLFOX alone as second line therapy in patients with metastatic pancreatic cancer that has progressed during or following a first line Gemcitabine containing regimen.

Endometrial/Peritoneal/Ovarian Cancers

UPCI 17-118 (GY009): A randomized, Phase II/III study of pegylated liposomal doxorubicin and CTEP-supplied atezolizumab (IND #134427) vs. pegylated liposomal doxorubicin/bevacizumab and CTEP-supplied atezolizumab vs. pegylated liposomal Doxorubicin/Bevacizumab in platinum resistant ovarian cancer.

UPCI 17-155 (GY011): A randomized surgical window pilot investigation of the relationship of short term medroxyprogesterone Acetate (NSC #26386) compared to medroxyprogesterone acetate plus entinostat (NSC #706995) on the morphologic, biochemical and molecular changes in primary endometrioid adenocarcinoma of the uterine corpus.

Prostate Cancer

UPCI 17-095: A Phase III, multicenter, randomized, study of androgen annihilation in high-risk biochemically relapsed prostate cancer.

UPCI 16-195: A Phase III, multicenter, randomized, study of atezolizumab (Anti-Pd-L1 Antibody) in combination with enzalutamide Vs. enzalutamide alone in patients with metastatic castration-resistant prostate cancer after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen.

UPCI 17-035: A Phase III randomized double-blind placebo-controlled multicenter trial testing ipatasertib plus abiraterone plus prednisone/prednisolone, relative to placebo plus abiraterone plus prednisone/prednisolone in adult male patients with asymptomatic or mildly symptomatic previously untreated metastatic castrate-resistant prostate cancer.

Sarcoma

UPCI 12-104: A Phase IB of II study of vorinostat in combination with gemcitabine and docetaxel in advanced sarcoma.

UPCI 16-209: A randomized Phase III trial of TRC105 and pazopanib vs. pazopanib alone in patients with advanced angiosarcoma (Tappas).

Thyroid

UPCI 16-121: A Phase II study of molecular markers to guide extent of initial thyroid surgery for patients with newly diagnosed papillary thyroid cancer

For a complete list of clinical trials please call 412-623-4861.